ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

inclisiran

Also written as “Inclisiran”, “Inclisiran Sodium” and “ALN-PCSSC”.

Its studies are mostly in Hypercholesterolemia · Atherosclerosis · Homozygous Familial Hypercholesterolemia · Acute Coronary Syndrome · Hyperlipoproteinemia Type II, led by 2 companies.

Drug pageInclisiran: every studyAll 51 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 13, 202137 company-led studies, 15 open or runningNext primary completion: Nov 27, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only3615 open or runningphase 4since Dec 13, 2021Nov 3, 2015Nov 27, 2026phase 4 · NCT06501443
Alnylam Pharmaceuticals10 open or runningphase 1since Dec 5, 2014Dec 5, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alnylam Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 5, 2014First study: phase 1 study in HypercholesterolemiaFirst studyNCT02314442 · 70 enrolled · United Kingdom
  2. Dec 9, 2015Named inclisiranINNProposed as its International Nonproprietary Name in WHO's List 114

TargetBeta

PCSK9 →read by rule
“The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SYH2053ruleCSPC Pharmaceutical Groupphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

The one study Alnylam Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02314442Hypercholesterolemia · United Kingdom1CompletedMay 201570

How it is read

Names in the registry

  • “Inclisiran”, 16 entries
  • “Inclisiran Sodium”, 4 entries
  • “inclisiran”, 3 entries
  • “ALN-PCSSC”, 3 entries
  • “Inclisiran sodium 300 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.